The Future of 
Vascular Bio-Technology


Integene was founded in 2010 by Prof. Keith Webster to capitalize patented gene therapy technology for the treatment of ischemia-related disease including coronary and peripheral artery disease and solid tumors.

For the past 20 years top scientists in the USA and UK have striven to effectively harness oxygen-regulated gene enhancers (HIF-1 & 2) to target therapeutic genes to ischemic/hypoxic tissues. The goal is to achieve differential expression of transgenes such that therapeutic levels are achieved in ischemic tissue with negligible expression or biological impact on surrounding normoxic tissues.  So far all strategies have failed either because of insufficient expression in target ischemic cells or leaky expression in normal tissues. Tight control of leaky expression is essential to avoid adverse side effects of toxic genes delivered to hypoxic tumors or pro-angiogenic genes targeted to ischemic muscle.  In a novel approach, Dr. Webster and his team at the University of Miami, Florida combined HIF-1 enhancers in tandem arrays with optimized gene silencer elements such that transgene expression is robust and "therapeutic" in targeted ischemic tissue but quiescent in surrounding normoxic tissues.

Preclinical research to date has shown that this technology combined with approved combination therapies (plasmids and/or stem cells) provides optimal outcomes in animal models of PAD.  Because there is no pharmacology to treat PAD, and all biotech approaches so far have failed in clinical trials, the unmet clinical need is urgent.  We have received FDA guidelines to proceed to IND applications for PAD, and are planing to initiate clinical trials during 2019.  Protocols for targeting hypoxic tumors are being developed in parallel.

Integene has an experienced team of advisors for scientific, business,  regulatory, and clinical development. 

Website Builder